


1645

Please type a plus sign (+) inside this box +


PTO/SB/21 (08-00)


Approved for use through 10/31/02. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<div style="text-align: center;">  <h2 style="margin: 0;">TRANSMITTAL FORM</h2> <p style="font-size: small;">(to be used for all correspondence after initial filing)</p> </div>	<b>Application Number</b>	09/955,858	<div style="transform: rotate(90deg);"> <b>RECEIVED</b>  MAR 06 2002  TECH CENTER 1600/2900 </div>
	<b>Filing Date</b>	September 18, 2001	
	<b>First Named Inventor</b>	Charles A. Nicolette, et al.	
	<b>Group Art Unit</b>	1645	
	<b>Examiner Name</b>	Not Yet Assigned	
	<b>Attorney Docket No.</b>	GZ 2096.00	

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declarations  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement w/Form PTO-1449  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copies of 75 References and return Postcard
<div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <input type="checkbox"/> Remarks </div> <div style="width: 70%;"></div> </div>		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	Antoinette F. Konski Michele Todd Wasmuth McCutchen, Doyle, Brown & Enersen, LLP Three Embarcadero Center, Suite 1800 San Francisco, California 94111
Signature	
Date	February 11, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"	
Date of Deposit: February 11, 2002	
<p>I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail on the date indicated above and is addressed to Commissioner for Patents, Washington, D.C. 20231.</p> <div style="text-align: center; margin-top: 20px;">   Jocelyn L. Lee </div>	

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



GZ 2096.00

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on this date: February 11, 2002.

By: Jocelyn L. Lee Name of person signing: Jocelyn L. Lee

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application for:

Charles A. NICOLETTE, et al.

Serial No.: 09/955,656

Filing Date: September 18, 2001

For: METHOD TO IDENTIFY ANTIBODY  
TARGETS

Examiner: Not Yet Assigned

Group Art Unit: 1645

RECEIVED  
MAR 09 2002  
TECH CENTER 1600/2600

#4  
\$1unkett  
\$11/02

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

**I. Timing of the Information Disclosure Statement:**

This Information Disclosure Statement is filed:

- ☐ With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- ☐ Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
- ☒ Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

This Information Disclosure Statement is filed:

- ☐ After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the

undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No.[ ] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.

This Information Disclosure Statement is filed:

- ☐ After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.

The undersigned certifies that:

- ☐ Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

## II. Copies of the Cited Items:

- ☒ Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
- ☐ Copies of only the following items listed on the attached Form PTO-1449 are enclosed: \_\_\_\_\_.
- ☐ Copies of those items which are marked with an asterisk (\*) in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. \_\_\_\_\_, filed \_\_\_\_\_ and relied upon in this application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).
- ☐ Copies of those items which are marked with an asterisk (\*\*) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

### III. Concise Explanation of Relevance:

- ☒ A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
- ☐ A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).

### IV. Conclusion:

Citation of the above documents shall not be construed as:

1. an admission that the documents are necessarily prior art with respect to the instant invention;
2. a representation that a search has been made, other than as described above; or
3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. 50-1189, Billing Reference No.: 19442-7240 for any additional fees required in connection with the filing of this Information Disclosure Statement. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

DATE: February 11, 2002

Respectfully submitted,

By: 

Antoinette F. Konski

Registration No.: 34,202

Michele Todd Wasmuth

Registration No.: 43,239

McCutchen, Doyle, Brown & Enersen, LLP  
Three Embarcadero Center, Suite 1800  
San Francisco, California 94111  
Telephone: (650) 849-4950  
Telefax: (650) 849-4800

Form PTO-1449	<b>FEB 26 2002</b> PATENT & TRADEMARK OFFICE	Docket No. GZ 2096.00	Appl. No. 09/955,656
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. Nicolette, et al.	
(use several sheets if necessary)		Filing Date: September 18, 2001	Group Art Unit 1645

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1	12/23/86	4,631,211	Houghten			
	2	07/28/87	4,683,195	Mullis et al.			
	3	07/28/87	4,683,202	Mullis			
	4	06/28/88	4,754,065	Levenson et al.			
	5	01/24/89	4,800,159	Mullis et al.			
	6	04/23/91	5,010,175	Rutter et al.			
	7	04/23/96	5,510,240	Lam et al.			
	8	12/09/97	5,695,937	Kinzler et al.			
	9	05/05/98	5,747,299	Bloom et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
	10	01/05/95	WO 95/00655	Graham et al.			
	11	05/04/95	WO 95/11984	Gregory et al.			
	12	06/22/95	WO 95/16775	Guo et al.			
	13	10/12/95	WO 95/27071	Zhang et al.			
	14	08/01/96	WO 96/23060	Cohen et al.			
	15	12/11/97	WO 97/46256	Webb et al.			
	16	10/22/98	WO 98/46785	Gong et al.			
	17	04/13/00	WO 00/20460	Sahin et al.			

## OTHER DOCUMENTS


(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	18	Abrahamsen, T.G., et al. "Stimulatory Effect of Counterflow Centrifugal Elutriation in Large-Scale Separation of Peripheral Blood Monocytes Can Be Reversed by Storing the Cells at 37°C" <i>J. Clin. Apheresis</i> 6:48-53 (1991).
	19	Adams, M.D., et al. "Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project" <i>Science</i> 252:1651-1656 (June 1991).
	20	Alwine, J.C., et al. "Method for Detection of Specific RNA's in Agarose Gels by Transfer to Diazobenzoyloxymethyl-paper and Hybridization with DNA Probes" <i>PNAS</i> 74(12):5350-5354 (December 1977).
	21	Boczkowski, D., et al. "Dendritic Cells Pulsed with RNA are Potent Antigen-presenting Cells In Vitro and In Vivo" <i>J. Exp. Med.</i> 184:465-472 (August 1996).
	22	Chaney, L.K., et al. "Coating Cells with Colloidal Silica for High Yield Isolation of Plasma Membrane

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.




Form PTO-1449		Docket No. GZ 2096.00	Appl. No. 09/956,656
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. Nicolette, et al.	
(use several sheets if necessary)		Filing Date: September 18, 2001	Group Art Unit 21645
		Sheets and Identification of Transmembrane Proteins" <i>J. Biol. Chem.</i> 258(16):10062-10072 (August 25, 1983).	
23		Coulie, P.G. "Human Tumour Antigens Recognized by T Cells: New Respectives for Anti-Cancer Vaccines" <i>Mol. Med. Today</i> 3:261-268 (June 1997).	
24		Cwirla, S.E., et al. "Peptides on Phage: A Vast Library of Peptides for Identifying Ligands" <i>PNAS</i> 87:6378-6382 (August 1990).	
25		Del Giudice, G. "Hsp70: A Carrier Molecule with Built-In Adjuvanticity" <i>Experientia</i> 50:1061-1066 (1994).	
26		Devlin, J.J., et al. "Random Peptide Libraries: A Source of Specific Protein Binding Molecules" <i>Science</i> 249:404-406 (July 1990).	
27		Fagerberg, J., et al. "Human Anti-idiotypic Antibodies Induced a Humoral and Cellular Immune Response Against a Colorectal Carcinoma-associated Antigen in Patients" <i>PNAS</i> 92:4773-4777 (May 1995).	
28		Ferguson, M.A.J., et al. "Cell-Surface Anchoring of Proteins Via Glycosyl-Phosphatidylinositol Structures" <i>Ann. Rev. Biochem.</i> 57:285-320 (1988).	
29		Fodor, S.P.A., et al. "Light-Directed, Spatially Addressable Parallel Chemical Synthesis" <i>Science</i> 251:767-773 (February 15, 1991).	
30		Fradet, Y., et al. "Cell Surface Antigens of Human Bladder Cancer Defined by Mouse Monoclonal Antibodies" <i>PNAS</i> 81:224-228 (January 1984).	
31		Freudenthal, P.S., et al. "The Distinct Surface of Human Blood Dendritic Cells, As Observed After an Improved Isolation Method" <i>Proc. Natl. Acad. Sci.</i> 87:7698-7702 (October 1990).	
32		Furka, A., "General Method for Rapid Synthesis of Multicomponent Peptide Mixtures" <i>Int. J. Peptide Protein Res.</i> 37:487-493 (1991).	
33		Furka, A., et al. "Proteins and Nucleic Acids in Three Dimensions" 14 <sup>th</sup> <i>Int. Congress of Biochem.</i> 5:47 Abstract FR:013 (1988).	
34		Geysen, H.M., et al. "Strategies for Epitope Analysis Using Peptide Synthesis" <i>J. Immunol. Meth.</i> 102:259-274 (1987).	
35		Geysen, M.H., et al. "A Priori Delineation of a Peptide Which Mimics a Discontinuous Antigenic Determinant" <i>Mol. Immunol.</i> 23(7):709-715 (1986).	
36		Hedrick, S.M., et al. "Isolation of cDNA Clones Encoding T Cell-Specific Membrane-Associated Proteins" <i>Nature</i> 308:149-153 (March 1984).	
37		Herlyn, D., et al. "Anti-Idiotypic Antibodies Bear the Internal Image of a Human Tumor Antigen" <i>Science</i> 232:100-102 (April 1986).	
38		Hermonat, P.L., et al. "Use of Adeno-associated Virus as a Mammalian DNA Cloning Vector: Transduction of Neomycin Resistance Into Mammalian Tissue Culture Cells" <i>PNAS</i> 81:6466-6470 (October 1984).	
39		Hirose, S., et al. "Mammalian Glycosylphosphatidylinositol-Anchored Proteins and Intracellular Precursors" <i>Methods in Enzymol.</i> 250:582-614 (1995).	
40		Huang, J.H., et al. "Protein Transfer of Preformed MHC-Peptide Complexes Sensitizes Target Cells to T Cell Cytolysis" <i>Immunity</i> 1:607-613 (October 1994).	
41		Klenerman, P., et al. "The Effects of Natural Altered Peptide Ligands on the Whole Blood Cytotoxic T Lymphocyte Response to Human Immunodeficiency Virus" <i>Eur. J. Immunol.</i> 25:1927-1931 (1995).	
42		Lebkowski, J.S., et al. "Adeno-Associated Virus: a Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types" <i>Mol. Cell. Biol.</i> 8(10):3988-3996 (October 1988).	
43		Liang, P., et al. "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction" <i>Science</i> 257:967-971 (August 14, 1992).	

EXAMINER:

DATE CONSIDERED:


EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



RECEIVED  
MAR 06 2002  
TECH CENTER 1600/22800

Form PTO-1449		Docket No. GZ 2096.00	Appl. No. 09/955,656
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. Nicolette, et al.	
(use several sheets if necessary)		Filing Date: September 18, 2001	Group Art Unit: 1645
44	Lisitsyn, N., et al. "Representational Difference Analysis in Detection of Genetic Lesions in Cancer" <i>Methods in Enzymol.</i> <b>254</b> :291-304 (1995).		
45	Llorente, L., et al. "Role of Interleukin 10 in the B Lymphocyte Hyperactivity and Autoantibody Production of Human Systemic Lupus Erythematosus" <i>J. Exp. Med.</i> <b>181</b> :839-844 (March 1995).		
46	Maa, J., et al. "Structural and Functional Characterization of a Cell Surface Binding Protein of Vaccinia Virus" <i>J. Biol. Chem.</i> <b>265</b> (3):1569-1577 (January 25, 1990).		
47	Medof, M.E., et al. "Cell-Surface Engineering with GPI-Anchored Proteins" <i>FASEB J.</i> <b>10</b> :574-586 (April 1986).		
48	Medof, M.E., et al. "Inhibition of Complement Activation on the Surface of Cells After Incorporation of Decay-Accelerating Factor (DAF) Into Their Membranes" <i>J. Exp. Med.</i> <b>160</b> :1558-1578 (November 1984).		
49	Merrifield, R.B. "New Approaches to the Chemical Synthesis of Peptides" <i>Recent Progress in Hormone</i> <b>23</b> :451-482 (1967).		
50	Mehta-Damani, A., et al. "Generation of Antigen-Specific CD8 <sup>+</sup> CTLs from Naïve Precursors" <i>J. Immunol.</i> <b>153</b> :996-1003 (1994).		
51	Mosmann, T. "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays" <i>J. Immunol. Methods</i> <b>65</b> :55-63 (1983).		
52	Nair, S., et al. "Soluble Protein Delivered to Dendritic Cells Via pH-sensitive Liposomes Induce Primary Cytotoxic T Lymphocyte Responses In Vitro" <i>J. Exp. Med.</i> <b>175</b> :609-612 (February 1992).		
53	Needels, M.C., et al. "Generation and Screening of an Oligonucleotide-Encoded Synthetic Peptide Library" <i>PNAS</i> <b>90</b> :10700-10704 (November 1993).		
54	Niks, M., et al. "Towards an Optimized MTT Assay" <i>J. Immunol. Methods</i> <b>130</b> :149-151(1990).		
55	Ohlmeyer, M. H.J. et al. "Complex Synthetic Chemical Libraries Indexed with Molecular Tags" <i>PNAS</i> <b>90</b> :10922-10926 (December 1993).		
56	Paglia, P., et al. "Murine Dendritic Cells Loaded In Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes Against Tumor Antigen In Vivo" <i>J. Exp. Med.</i> <b>183</b> :317-322 (January 1996).		
57	Reilly, R.T., et al. "The Collaboration of Both Humoral and Cellular HER-2/neu-targeted Immune Responses Is Required for the Complete Eradication of HER-2/neu-expressing Tumors" <i>Cancer Research</i> <b>61</b> :880-883 (February 1, 2001).		
58	Roselli, M., et al. "Tumor Markers as Targets for Selective Diagnostic and Therapeutic Procedures" <i>Anticancer Res.</i> <b>16</b> :2187-2192(1996).		
59	Rouse, R. J.D., et al. "Induction In Vitro of Primary Cytotoxic T-Lymphocyte Responses with DNA Encoding Herpes Simplex Virus Protein" <i>J. Virology</i> <b>68</b> (9):5685-5689 (September 1994).		
60	Scott, J.K., et al. "Searching for Peptide Ligands with an Epitope Library" <i>Science</i> <b>249</b> :386-390 (July 27, 1990).		
61	Scott, A. M., et al. "Construction, Production, and Characterization of Humanized Anti-Lewis Y Monoclonal Antibody 3S193 for Targeted Immunotherapy of Solid Tumors" <i>Cancer Research</i> <b>60</b> :3254-3261 (June 15, 2000).		
62	Sette, A., et al. "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes" <i>J. Immunol.</i> <b>153</b> :5586-5592 (1994).		
63	Shevchenko, A., et al. "MALDI Quadrupole Time-of-Flight Mass Spectrometry: A Powerful Tool for Proteomic Research" <i>Anal. Chem.</i> <b>72</b> :2132-2141 (2000).		
64	Sinkovics, J.G., et al. "Vaccination Against Human Cancers (Review)" <i>Int. J. Oncol.</i> <b>16</b> :81-96 (2000).		
65	Spira, G., et al. "The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449		Docket No. GZ 2096.00		Appl. No. 09/835,656	
		Applicant(s) Charles A. Nicolette, et al.			
INFORMATION DISCLOSURE STATEMENT  (use several sheets if necessary)		Filing Date: September 18, 2001		Group Art Unit: 155	
		Assay" <i>J. Immunol. Methods</i> 74:307-315 (1984).			
	66	Steinman, R.M. "The Dendritic Cell System and its Role in Immunogenicity" <i>Annu. Rev. Immunol.</i> 9:271-296 (1991).			
	67	Steplewski, Z., et al. "Isolation and Characterization of Anti-Monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants" <i>PNAS</i> 82:8653-8657 (December 1985).			
	68	Thomas, R., et al. "Comparative Accessory Cell Function of Human Peripheral Blood Dendritic Cells and Monocytes" <i>J. Immunol.</i> 151(12):6840-6852 (December 15, 1993).			
	69	Trail, P. A., et al. "Monoclonal Antibody Drug Conjugates in the Treatment of Cancer" <i>Current Opinion in Immunol.</i> 10:584-588 (1999).			
	70	Tureci, O., et al. "Exploitation of the Antibody Repertoire of Cancer Patients for the Identification of Human Tumor Antigens" <i>Hybridoma</i> 18(1):23-28 (1999).			
	71	Van der Zee, R., et al. "Efficient Mapping and Characterization of a T Cell Epitope by the Simultaneous Synthesis of Multiple Peptides" <i>Eur. J. Immunol.</i> 19:43-47 (1989).			
	72	Veres, G., et al. "The Molecular Basis of the Sparse Fur Mouse Mutation" <i>Science</i> 237:415-417 (July 24, 1987).			
	73	Weiner, L.M. "Monoclonal Antibody Therapy of Cancer" <i>Semin. Oncol.</i> 26(5)(14):43-51 (October, 1999).			
	74	Zinn, K., et al. "Identification of Two Distinct Regulatory Regions Adjacent to the Human $\beta$ -Interferon Gene" <i>Cell</i> 34:865-879 (October 1983).			
	75	Zweierink, H.J., et al. "Presentation of Endogenous Peptides to MHC Class I-Restricted Cytotoxic T Lymphocytes in Transport Deletion Mutant T2 Cells" <i>J. Immunol.</i> 150(5):1763-1771 (March 1, 1993).			

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	